Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2021.0305
Mini-Review
|
Discovery of novel drugs and biomarkers drive breakthrough matched combinatorial therapy.
|
|
| |
Abstract
Next Generation Sequencing (NGS) and CRISPR -Cas technologies are transforming biomedical research towards Precision Medicine [1-3]
Particularly in cancer, an explosion in genome and transcriptome analysis has not only created a revolutionary roadmap but also is initiating to guide Precision Oncology [4] .
The potential and challenges of whole genome and transcriptome analysis in time and space by developing and validating novel prediction biomarkers and novel targeted drugs[5, 6] are described. Moreover, combination drug therapy matched the individual patients set of actionable mutations [7] are discussed Optimal individualized meaningful treatment is also discussed in this review.
(Citation: Gastric & Breast Cancer 2021; 16(1): 46-55)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
Dior Outlet
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 1 January 2021 |
|
